WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option
WILMINGTON, Del., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its initial public offering of 8,325,000 shares of its common stock at a public offering price of $19.00 per share.
– Expands Board of Directors with Two New Appointments – Wilmington, DE – August 24, 2020 – Prelude Therapeutics, a privately-held, clinical-stage precision oncology company, today announced that it has completed a $50 million Series C financing round led by Prelude’s two existing institutional
– Advances lead product into clinic and additional compounds into preclinical development – David Mauro, MD, PhD, as Chief Medical Officer, and Brian Piper, MBA, as Chief Financial Officer, join management team led by Founder and CEO, Kris Vaddi, PhD Wilmington, DE – June 12, 2019 – Prelude
